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Studies have shown that mesenchymal stromal cells (MSCs) are able to differentiate 
into extra-mesodermal lineages, including neurons. Positive outcomes were obtained 
after transplantation of neurally-induced MSCs in rats, rabbits and guinea pigs after 
nerve injury, but the effect of these cells is unknown in horses. Our objective was to 
test the ability of equine mesenchymal stromal cells to differentiate into cells of 
neuronal lineage, and to assess differences, if any, in morphology and protein 
expression. Additionally, we wanted to investigate if horse age and cell passage 
number contributed to the ability to achieve neural differentiation.   
 
The first part of this research focuses on assessing the potential of equine bone 
marrow-derived mesenchymal stromal cells to undergo differentiation into cells of 
neural lineage cells after prior demonstration of their stemness. It describes the 
optimization of in vitro conditions to induce neural differentiation of equine MSCs and 
the use of neural markers in equine MSCs, which has not been previously reported.   
 
Subsequent research focuses on further commitment of these neural cells into 
Schwann-like cells for possible transplantation into an acute peripheral nerve injury 
model in horses. After optimizing the laboratory conditions to induce Schwann cell 
differentiation of equine MSCs, their detachment from the tissue culture flasks 
resulted in poor viability. Therefore, undifferentiated MSCs were transplanted in the 
surrounding fascia after transecting the central portion of the anastomotic branch 
(ramus communicans) of the lateral and medial palmar nerves of the fore limbs in 
healthy horses. Approximately 45 days after the lesion was created, the whole nerve 
was removed for histological analyses. 
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Horses (Equus caballus) are herbivore-domesticated mammals that have played a 
crucial role in the development of the modern society.  Several breeds of horses have 
been used through the years for transportation, work in agriculture, wars, racing, 
sources of food, equestrian sports, and pets.  Furthermore, the horse industry has a 
direct effect on the economy of the USA of $39 billion per year, and $102 billion when 
the industry suppliers and employees factors are taken in consideration.1 The 
profound impact of the horse industry on the economy results from the creation of 
jobs, necessity of industrial supplies, agricultural production, generation of taxes, and 
entertainment investments. Veterinary medicine is, therefore, one important science 
to safeguard the stability of the horse industry. 
 
There are several breeds of horses (equines), most of which possess certain corporal 
characteristics that allow them to perform arduous physical work under various 
environmental conditions. Some of these anatomic and functional characteristics 
include a particular musculoskeletal system, a complex gastrointestinal system, and a 
high efficiency cardiovascular and respiratory apparatuses, that will provide them 
with satisfactory kinematics, energy, and adequate perfusion and oxygenation, 
respectively. Because horses are athletic animals and approximately 44-53% of their 
body weight is constituted solely by muscle,2 a disturbance of any of the structures of 
the musculoskeletal system (i.e. muscles, tendons, bones, joints, ligaments, and their 
associated blood and lymphatic vessels, and nerves) will produce poor performance 
and, consequently, financial or emotional losses. The musculoskeletal system of the 
horse is vast; in this research, however, a particular interest is given to the structures 












Peripheral nerve injuries occur commonly in horses but the available options for 
managing them are limited. Cell therapy via autograft is the preferred method for 
nervous tissue repair in human medicine but there are high risks for complications at 
the donor site and the number of Schwann cells yielded from this donor nerve is 
generally low. Cell therapy via transplantation of autogeneic or allogeneic 
mesenchymal stromal cells (MSCs) provides an alternative approach for yielding high 
number of cells without the risks of causing damage to the donor site; it has also 
revealed promising results after transplantation in peripheral nerve injuries 
artificially created in laboratory animals or when transplanted in clinical cases in dogs 
and humans, but this is unknown in horses. Based on in vitro studies, MSCs have anti-
inflammatory, immunomodulatory, and paraendocrine properties that provide the 
conditions necessary for tissue repair. The method of delivery of these cells has largely 
been studied and might depend on the site of lesion and practicability of the 
procedure. Further research is necessary for evaluating methods of labeling, tracking 
and delivering these cells in horses suffering from peripheral nerve injuries. 
 
 
Generalities of the nervous system 
 
The nervous system involves a complex network of cells that ultimately has the 
functions of acquiring information from the exterior of the animal, processing it, and 
delivering specific signals to specific organs based on these external stimuli. It is, 
therefore, that the nervous system is composed of different specialized cells, which 
originate from the ectodermic layer during the embryonic development.  
 
The nervous system is divided into the central nervous system (CNS) and the 
peripheral nervous system (PNS). Briefly, the CNS comprises the structures within 
the encephalon (i.e. brain, brain stem, cerebellum, etc.) and spinal cord. On the other 
hand, ganglia, cranial and spinal nerves comprise the PNS.3 It is worth mentioning 
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that both divisions of the nervous system continuously interact with each other. For 
purposes of this research, however, a particular interest is given to the PNS.  
 
Additionally, the PNS is subdivided into autonomic PNS and somatic PNS. The 
autonomic PNS encompasses the nerve fibers (axons) that innervate involuntary or 
autonomic structures, such as the heart, smooth muscle and glands.3 The somatic PNS, 
instead, involves the axons that give input to the musculoskeletal system, which are 
mostly involved with voluntary activity.  
 
An alternative division of the nervous system is based in its functional properties: 
afferent (sensory) and efferent (motor).4 
 
Peripheral nerves. These include the 12 pairs of cranial nerves located in the encephalon, 
and the spinal nerves, which arise from the spinal cord. Each nerve consists of parallel 
bundles of nerve fibers (axons), which can be afferent or efferent. A surrounding 
sheath of connective tissue provides support to these nerves and their associated 
blood and lymphatic vessels. Additionally, these axons can be myelinated or non-
myelinated.4 Myelinated axons are surrounded by a myelin sheath formed by 
supporting cells (also known as satellite cells): oligodendrocytes, in the CNS; and 
Schwann cells in the PNS. Myelin is composed of the cell membrane from Schwann 
cells, which is approximately 80% lipid in nature; hence, it has insulation properties. 
The myelin sheath surrounding the axon is a layer regularly segmented by the nodes 
of Ranvier that help in the transmission of a nerve impulse in a saltatory and extremely 
fast manner (Figure 1.1). Peripheral nerves, consequently, can also be classified by 
their speed of conduction (A, B or C fibers) and their fiber size (μm of diameter).5 The 
fastest nerve fibers are usually myelinated and thicker (i.e. α and β subtypes of the A 
fibers, which transmit motor and sensory impulses to skeletal muscle and skin 
receptors). On the other hand, the slowest nerve fibers are non-myelinated and of 
small diameter (i.e. C fibers that transmit deep, non-localized pain). 
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In the CNS, each oligodendrocyte forms myelin sheaths for up to 60 axons. In the PNS, 
on the other hand, only one Schwann cell exists for each segment of one axon. 
Moreover, the Schwann cells wrap around the axons in a spiral, which is clockwise in 
some segments and counterclockwise in others. These wrappings become tight as the 
axon matures, and the thickness of the myelin sheath will ultimately depend on the 




Figure 1.1 Peripheral nerve myelination 
 
 
Peripheral nerve conduction. Once a stimulus is perceived, an action potential (nerve 
impulse) starts at the initial segment of an axon and propagates along the plasma 
membrane of the cell. Before an action potential the interior of a nerve cell is negatively 
charged at approximately -80 millivolts (mV); this is called the resting membrane 
potential. The cell membrane allows the opening of ion channels that result in a rapid 
influx of ions, which will change the charge inside the cell. This change is called 
depolarization.3 Ion channels are particular to the cell type. For example, sodium 
channels are abundant in peripheral nerves; they open fast and allow a massive 
entrance of sodium inside the cell that will result in an extremely prompt action 
potential. Calcium channels are abundant on smooth muscle cells; they open in a 
slower manner, resulting in a more prolonged action potential. Finally, after the 
impulse has propagated throughout the cell, other ion channels (e.g. potassium) open 
and allow the exit of positive ions, so the original resting membrane potential can be 
restored (hyperpolarization).  
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The speed of conduction is correlated with the axonal diameter of the nerve fiber. 
Additionally, myelin sheath thickness correlates with nerve diameter. These 
characteristics and the saltatory conduction of the nerve impulse at the nodes of 
Ranvier in myelinated nerves make myelinated nerves the fastest nerves for 
transmission of an impulse, at a velocity of 70-120 meters per second in Aα fibers. 
 
    
Concepts in regenerative medicine: stem cells 
 
The purpose of regenerative medicine is to create functional tissues for repairing or 
replacing tissues or organs that have been damaged or lost because of accidents, 
diseases, and age,6 usually via transplantation of cells, tissues or organs that were 
previously cultured or created in the laboratory. 
 
Stem cells are undifferentiated cells that have the ability to proliferate (self-renew) for 
an indeterminate time during the life of the organism, and to differentiate into mature, 
specialized cells given the right conditions (plasticity).6,7 The term “stem cell”, 
however, has been used indiscriminately to denote certain types of cells with specific 
characteristics and it is, therefore, important to clarify some terms used in the field of 
cellular therapy for regenerative medicine.  
 
Stem cells can be of embryonic or adult origin. Based on their ability to differentiate, 
those stem cells capable of differentiating into all cell types, including extra-embryonic 
membranes and tissues, are called totipotent stem cells and they are solely found in the 
zygote and early embryo.6,8 Pluripotent stem cells are able to differentiate into all cell 
types from the 3 germinal layers that constitute an implanted embryo (ectoderm, 
mesoderm and endoderm), but not into extra-embryonic tissues.6,7 Multipotent stem 
cells are capable of differentiating into various cell types of a specific germinal layer. 
Finally, unipotent stem cells can only differentiate into a single mature cell type.6  
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Types of cell transplants. Depending on the source, cell, tissue, or organ, transplants are 
called xenogeneic, allogeneic or autologous. Briefly, xenogeneic implies the 
transplantation of cells, tissue or organs from one species to another; for example, 
human cell transplants into rats for research purposes. Allogeneic transplantation 
involves different individuals from the same species; for example, human blood 
donors. Autologous transplantation involves taking tissue from an individual in order 
to implant it at another site on that same individual (also known as autograft); for 
example, removal of a portion of the ischium bone in order to graft it into a bone defect 
(in a bone other than ischium). 
 
In human and veterinary practice, the source of transplants is either allogeneic or 
autologous. The concern in performing allogeneic transplantation of cells, tissue or 
organs is the possibility of rejection, which is due to the immune response of the host. 
A disadvantage of autologous transplantation is the possibility of causing morbidity 
at the donor site, which was previously inexistent.  
 
 
Mesenchymal stromal cells (MSCs) 
 
This term refers to non-hematopoietic (non-blood) adult multipotent stem cells that 
originate from diverse adult tissues. It is unknown if these cells are the same 
throughout the different tissues.8 The term mesenchyme denotes a transient, loose 
tissue conformed by cells within a mesh of fluid and extracellular protein matrix, 
during embryonic and fetal development. It is mainly derived from the mesoderm 
and it directly gives rise to connective tissue throughout the body and to most organs 
in the body (morphogenesis) after interacting with the epithelium.9 The mesenchyme, 
consequently, is crucial in the embryonic life, but can also be found in small quantities 
in bone marrow, fat, muscles, and dental pulp. The term stromal, on the other hand, 
refers to cells that constitute the connective tissue of every organ.6 Certain 
mesenchymal stromal cells (MSCs) are capable of displaying multipotency and are 
subsequently called mesenchymal stem cells.10,11  
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Criteria for MSCs  
 
To properly refer to MSCs, the International Society for Cellular Therapy (ISCT) has 
specified that “multipotent mesenchymal stromal cells” is a term preferred over 
mesenchymal stem cells, because not all have stem cell characteristics. Three minimal 
criteria for defining human MSCs have been established: 1. adherence to plastic when 
maintained in standard culture conditions, 2. expression of specific surface antigens, 
and 3. potential for multipotent mesenchymal differentiation (plasticity).10 
 
It is important to mention that currently there is controversy on the use of the 
terminology regarding mesenchymal stem cells and mesenchymal stromal cells 
(MSCs).12 There is lack of a specific marker expressed solely by MSCs. Several 
characteristics of these cells, however, have been taken in conjunction to propose the 
minimal criteria to define MSCs.10 In addition, there are differences between MSC 
populations obtained from various sources, adding confusion to the concept of MSC. 
 
Surface antigen expression of MSCs. The recognition of surface antigens permits the 
identification of a particular cell population. When performing flow cytometry, 
approximately 95% of the MSC population should mainly express CD73, CD90 and 
CD105 surface antigens. The MSCs should also lack expression of the hematopoietic 
antigens CD45, CD34, CD14, CD11b, CD19 and human leukocyte antigen (HLA) class 
II.10 It is important to mention that for a proper identification of a MSC population. It 
is, consequently, important that the three criteria established by the ISCT are taken 
simultaneously in consideration for defining MSC.   
 
Sources of MSCs  
 
Mesenchymal stromal cells have been isolated from various tissues in humans, pigs, 
rodents, rabbits, dogs, cats, small ruminants,13 and horses.14 The most commonly 
identified sources for MSC isolation are adult adipose tissue15 bone marrow, compact 
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bone, dental pulp,16 peripheral blood,17 umbilical cord blood, amniotic fluid, and other 
fetal tissues.18,19  
 
Bone marrow-derived versus adipose tissue-derived MSCs. Because of the relative ease of 
accessibility, MSCs are most commonly obtained from bone marrow and adipose 
tissue in human and veterinary medicine. Bone marrow aspiration is considered an 
invasive procedure in human medicine, but in equine medicine this is not the case 
because of the relative straightforwardness of the procedure when aspirating bone 
marrow from the sternum or the hip in horses. Bone marrow aspiration is also faster 
and leads to less complications than aspirating adipose tissue for obtaining MSCs 
from a horse.  
 
Both bone marrow-derived and adipose tissue-derived MSCs are effective in their 
ability to differentiate into cells of mesodermal and extra-mesodermal lineages and 
both are able to express the aforementioned typical markers for MSCs. Furthermore, 
cells derived from both sources appear to be similarly proliferative, although it has 
been reported by some groups that adipose tissue-derived MSCs may yield higher 
numbers of MSCs.20 And, most importantly, both sources of MSCs seem to have 
immunosuppressive and anti-inflammatory properties. 
 
 
Biological features of MSCs  
 
By definition MSCs are multipotent and self-renew quickly. These features make 
MSCs an alternative source for tissue regeneration. Additionally, regardless of their 
source, it has been reported that these cells are well tolerated by the host after 
transplantation (allogeneic transplantation). 
 
Immunomodulatory properties of MSCs. After transplantation, MSCs are well tolerated 
by the host. In vitro research has proved that MSCs are immunosuppressive by their 
ability to inhibit activated cytotoxic T cells and natural killer cell proliferation, and 
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downregulate B cell proliferation and differentiation.21,22 Furthermore, this feature 
appears to be augmented if an active inflammatory response occurs in the body. 
Likewise in animal models, MSCs were able to ameliorate or inhibit acute rejection 
and or prolong allograft survival.22,23 An explanation for this would be the ability of 
MSCs to downregulate CD86 and MHC class II to consequently impair the ability of 
macrophages to activate the antigen-specific CD4+ T cells.24  
 
More recently, it has been discovered that human bone marrow-derived MSCs express 
toll-like receptors (TLR) 3 and 4.25 These TLR are involved in danger signals that 
certain cells produce after they have been invaded by microorganisms, endotoxins or 
certain nucleic acids, activating the inflammatory cascade and preventing the 
suppression of T cell proliferation. Therefore, MSCs have the potential for both 
inhibitory and stimulatory effects on the immune system. 
 
Anti-inflammatory properties of MSCs. During acute inflammation, the body produces 
both pro-inflammatory and anti-inflammatory cytokines (mainly, interleukins β1 [IL-
β1] and 6 [IL-6], and tumor necrosis factor α [TNFα]) and other factors in an attempt 
to defend itself from the insult, but also to enhance healing. Over-production of pro-
inflammatory factors produces undesirable effects in the body, because it results in an 
exaggerated inflammatory response. There are reports of MSCs being able to 
counteract the effects of inflammation. Mesenchymal stromal cells are capable of 
upregulating TGF-β1, an anti-inflammatory cytokine, shifting the macrophage 
phenotype from M1 (inflammatory) to M2 (anti-inflammatory), secreting superoxide 
dismutase, an enzyme that helps reduce oxidative stress, stimulating the synthesis of 
other chemokines or growth factors, and recruiting other cells to the site of injury.26-29 
On the other hand, MSCs are able to over produce prostaglandin E2 at levels that 




Additionally, MSCs are capable of migrating and homing into injured tissues and 
even though the mechanisms have not been discovered yet, it is thought that tyrosine 
kinase and TLR-3 receptors might mediate their activity.25,30 
 
Paracrine influence of MSCs in tissue regeneration. It is alleged that MSCs enhance tissue 
regeneration not only by their ability to stimulate endogenous progenitor or stem cells 
or to differentiate into cells of other lineages, but also in an indirect manner by 
secreting growth factors which are involved in neo-vascularization and tissue 
protection (i.e. reducing oxidative stress), and by inhibiting the host’s immune 
response after transplantation and promotion of healing.  
 
Growth factors are extra-cellular macromolecules that influence the function of target 
cells by binding to a cell surface receptor. Similarly, direct cell membrane-to-cell 
membrane contact mediated by adhesion molecules might also influence the function 
of other cells.31 For example, MSCs are known to secrete insulin-like growth factor 1 
(ILGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (fGF-
2), platelet-derived growth factor (pdGF), nerve growth factor (NGF), hepatocyte 
growth factor (hGF), and several interleukins (IL).15,26,32-34 The secretion of these 
factors is triggered by different stimuli, such as hypoxia, ischemia, and free radicals. 
 
The direct and indirect effects of MSCs are vast and still incompletely understood. 
Research performed in laboratory animals for nervous system diseases such as 
Alzheimer’s disease, spinal cord injuries, or peripheral nerve injuries has 
demonstrated that the transplantation of MSCs provide neuroprotective effects by 
reducing neuronal sensitivity to glutamate, reducing oxidative stress and apoptosis, 
inhibiting the production of extracellular matrix, and by stimulating the synthesis of 
growth factors needed for regeneration.26,35,36 
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Cell plasticity of MSCs. 
 
As recognized by the ISCT, MSCs should be capable of acquiring phenotypic markers 
for osteoblasts, chondrocytes and adipocytes, under the proper culture conditions.37 
To demonstrate this, staining with Alizarin Red for osteoblasts, Alcian Blue for 
chondrocytes, and Oil-Red-O for adipocytes should be performed.10,38 Mesenchymal 
stromal cells from bone marrow and adipose tissue, however, have also been 
demonstrated to differentiate into cells from other mesodermal lineages (i.e. 
myocytes, cardiac myoblasts, tenocytes, fibroblasts)39,40 and into cells of extra-
mesodermal lineages (i.e. hepatocytes and neuronal cells).41-43  
  
Neural differentiation of MSCs. In vitro research has shown that after induction with 
specific culture medium MSCs suffer morphological changes, such as contraction of 
the cell body and appearance of one or multiple processes, which resemble the 
phenotype of a cell from neural.41,44-48 Several researchers refer to these cells as 
“neuron-like cells” but this term has not been defined by the ISCT. Yet, these cells 
continue to modify their morphology after the culture medium conditions are further 
changed. For instance, after exposing MSCs to a cytokine cocktail composed mainly 
of growth factors following previous pre-incubation with beta-mercaptoethanol and 
all-trans-retinoic acid, these cells acquire a different phenotype than the typical 
fibroblast-like morphology of an undifferentiated MSC; fibroblasts are flat and lack 
structural assymetry.44,49-52 The morphological features that these MSCs acquire after 
exposure to this media resemble those of a Schwann cell, that is an oval-shaped cell 
body and bipolar or tripolar extensions, giving an overall spindle shape. Furthermore, 
these cells are able to express specific protein markers of Schwann cell.34,44,50,53 And, 
most remarkably, models in laboratory animals have demonstrated that the functional 
properties of these cells after transplantation during spinal cord or peripheral nerve 
injury promote myelination and axonal regeneration of the spinal cord or injured 
nerve segments,45,48,52,54,55 demonstrating that MSCs have broader plasticity than 
previously thought. Researchers refer to these cells as “Schwann-like cells”. 
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The complete mechanisms that mediate the fate of these MSCs towards neural 
commitment are currently unknown. It has been discovered, however, that there is a 
transcriptional switch of MSCs towards neuroglial lineage, mediated by beta-
mercaptoethanol and all-trans-retinoic acid.51 Furthermore, there are also pro-neural 
genes that code for proteins that will eventually determine the fate of progenitor cells 
and their differentiation.56,57  
 
Caution needs to be taken, nevertheless, not to confuse the term “neuron-like cells” 
with neurons. This term denotes MSCs (mesodermal origin) that were chemically 
induced for differentiation and acquired certain morphological characteristics, which 
is unrelated to the development of any of the nervous system cells, including neurons. 
During embryological development, the neural crest cells migrate in different 
directions and give rise to various ectodermal and mesodermal cell populations, 
including neurons, supportive cells of the nervous system (glial cells, Schwann cells, 
meningeal cells), endocrine cells (adrenal medulla, calcitonin-producing cells, carotid 
body cells), and mesodermal derivatives (connective and skeletal tissue of the head, 
smooth muscle cells on large vessels, and dermis of the neck and face). The fate of the 
neural crest cells depends on where they migrate and stay, but it is thought that some 
neural crest cells were already committed to their fate, while others are multipotent.58 
The term “neuron-like cell”, consequently, should be avoided when referring to 
MSCs. A more appropriate terminology should be proposed, but for purposes of this 
research the term “neuron-like cells” will be replaced with “neural crest-like cells”. 
 
Schwann cell trans-differentiation of MSCs. Transdifferentiation implies further 
commitment or specialization of the cells’ fate in the cascade of neural differentiation, 
in this case, towards a Schwann cell phenotype. Dezawa et al (2001) described a 
protocol for the differentiation of MSCs into Schwann-like cells. This protocol 
involved pre-incubation of the MSCs with beta-mercaptoethanol for 24 h, and all-
trans-retinoic acid for 3 days; this was then replaced by a cytokine cocktail containing 
basic fibroblastic growth factor (bFGF), pdGF, forskolin and heregulin (a type of 
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neuregulin-1), for 7 days.52 Other researchers have done some modifications of this 
protocol. 
 
It has been hypothesized that MAPK signaling is involved in the differentiation of 
Schwann precursor cells to mature Schwann cells (myelin producing Schwann cells). 
The combination of some growth factors, such as bFGF and PDGF, stimulate the 
activation of this MAPK cascade,59 while the role of forskolin is to upregulate the 
levels of intracellular cAMP for proliferation.60 This upregulation of cAMP has 
additional neuroprotective effects; it retards diffuse axonal damage and has anti-
inflammatory and immunomodulatory functions.61 Other factors, such as Krox-20, 
activate the myelin genes and thus promote maturation of these Schwann cell 
precursors;46,57 Krox-20 also suppresses the Notch signaling that is involved in 
proliferation of glial cells, including the Schwann cell precursors.58,62 Similarly, 
heregulin influences proliferation, survival and maturation of glial cells, by inducing 
neural crest cells into Schwann cells via the MAPK cascade.57    
 
 
Peripheral nerve injuries in the horse 
 
 
Nerves can be injured because of trauma, toxicity, metabolic, or infectious disease.  
Less frequently, degenerative and hereditary disorders pose a threat. Trauma to the 
peripheral nerves can result from thermal or chemical injuries, compression, crushing, 
stretching or transection.26,63 Following injury the blood-nerve barrier permeability 
increases and a cascade of events leads to the activation of local macrophages and 
monocytes that will remove myelin and axon debris, and to Schwann cell proliferation 
that will produce neurotrophic factors and extracellular matrix molecules needed for 
axonal regrowth and re-myelination. This inflammatory response results in Wallerian 
degeneration in the distal stump of the injured nerve.26,30,35,46-48,56,58,63,64  
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In veterinary practice, there are numerous peripheral nerve disorders (neuropathies) 
commonly observed in horses depending on their physical activity, clinical status or 
environment. Examples of these neuropathies include stringhalt, recurrent left 
laryngeal neuropathy (laryngeal hemiplegia), suprascapular nerve injury (Sweeney), 
facial, radial and femoral nerve paralysis, and polyneuritis equi (Figure 1.2). All of 
these are a cause of poor performance and economic loss to the equestrian industry. 
Furthermore, horses with peripheral nerve disorders are difficult to manage, and 
clinicians rely primarily on treating affected horses with anti-inflammatory drugs and 
physical therapy. Their treatment often results in financial hardship for the owner, 
and the outcome is usually correlated with the severity of the lesion and the interval 
before initiation of treatment. The final outcome for the horse is sometimes euthanasia. 
 
 
Figure 1.2 Examples of peripheral nerve disorders in horses: laryngeal hemiplegia (a) 
and stringhalt (b) 
 
 
Types of nerve injuries  
 
A classification for peripheral nerve injuries based on the severity of damage and 
nervous components involved was described by Seddon (1943).65 The least severe 
damage to the nerve is called neurapraxia, which is characterized by local ischemia 
 16 
(lack of blood perfusion) and discriminatory demyelination of the myelin sheath; this 
is reversible and the continuity of the axon itself is intact, thus conduction within the 
nerve proximal and distal to the lesion remains intact. An example of this is the 
damage that results from prolonged nerve compression. 
 
The second type of injury is axonotmesis, in which there is disruption of the myelin 
sheath and the axon. Here, the connective tissue layers surrounding bundles of axons 
and their associated blood and lymphatic vessels, perineurium and epineurium, 
remain intact. This injury results in Wallerian degeneration and part of the axon 
disintegrates distal to the site of injury. Examples of this are nerve damage following 
displaced fractures and nerve crush injuries. 
 
Finally, the most severe type of nerve injury based on this classification is neurotmesis, 
in which there is complete nerve transection and, therefore, disruption of the axons, 
myelin and the endoneurium (the immediate connective tissue layer that engulfs 
axons). This also results in Wallerian degeneration but there is complete transection 
of the nervous structures. The prognosis for this type of injury is also the poorest, and 
even with surgical repair and grafting, the results are not always rewarding. This type 
of injury can be consequence of severe ischemia or nerve transection.63 
 
 
The role of Schwann cells in peripheral nerve injuries 
 
In the PNS, the Schwann cells are glial cells that produce myelin, which is 
indispensable for fast conduction of nerve impulses. These cells additionally support 
axonal regeneration by the provision of several neurotrophic factors, hence, 
contributing to the creation of a microenvironment that is able to nourish, attract and 
stimulate other cells to aid in nerve protection and regeneration after an injury.35,66 
 
As is the case for other types of cells, there is not a sole marker for identifying Schwann 
cells; a combination of known markers along with functional studies is preferred 
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before inferring conclusions on the ability of MSCs to differentiate into Schwann-like 
cells. Markers frequently used for the identification of Schwann cells are S100, p75, 
Krox20, CD104, and glial fibrillary acidic protein (GFAP).46,49,50,56 
 
S100 is the most commonly reported marker for Schwann cell. It is a calcium binding 
protein constituted by 2 subunits: α and β (each approximately 10 kilo Daltons). It is 
considered to be a cell growth regulator but has other functions such as a protein and 
free fatty acid transport, or causing an increase in membrane permeability to cations, 
which are likewise attributed to this protein. Cells known to express S100 are glial 
cells, Schwann cells, melanocytes, chondrocytes, adipocytes, Langerhan’s cells, 
interdigitating cells and some tumor cells (i.e. melanomas, Schwannomas). 
Consequently, S100 is not a specific marker for Schwann cells; nevertheless, there have 
been reports of undifferentiated MSCs expressing S100,46 implying the potential of 
MSCs towards neural differentiation. In humans, cells expressing S100 have been 
subclassified into cells that express S100b, S100a and S100ao. Schwann cells and cells 
from the hypophysis express S100b.31 Other properties attributed to S100 are nerve 
protection, nutrition and induction for axonal regeneration.46 
 
GFAP is another marker commonly used to identify glial cells, including Schwann 
cells. We have found, however, that undifferentiated equine MSCs also express this 
protein, as previously reported by other researchers using undifferentiated MSCs 
from other species.67,68 GFAP has neuroprotective properties by modulating the 
Schwann cell response to nerve injury.46  
 
Similarly important, as it was mentioned in previous sections with undifferentiated 
MSCs, transplantation of either Schwann cells or MSCs differentiated into Schwann-
like cells has been demonstrated to directly or indirectly enhance tissue healing by the 
immunomodulatory, anti-inflammatory and paracrine functions that they exert on 




Cell therapy for nervous tissue repair: current research 
    
Studies performed in rats, guinea pigs, and rabbits have demonstrated that peripheral 
nerves can be regenerated.26,48,54,69,70 Even though the outcome is often disappointing. 
The most appropriate treatment for people with nerve injury is the insertion of an 
autograft into the gap in the transected nerve.70-72 Limitations, such as available donor 
nerves, donor-site morbidity, and limited supply of cultured Schwann cells, however, 
prevent autografting from having practical clinical applications.26,72 This is one reason 
why cell therapy with MSCs is intriguing; other factors include the ease of obtaining 
and expanding these cells in vitro to yield a high number for transplantation. 
 
 
Therapy with MSCs 
 
During the past decade, research for treating peripheral nerve injuries has been 
directed towards the use of cell therapy alone or combined with platelet rich plasma 
(PRP), grafts, or tissue-engineered biomaterials. Experimental models in laboratory 
animals and clinical trials in dogs have revealed that transplantation of either 
undifferentiated MSCs or Schwann-like differentiated MSCs into animals with 
peripheral nerve or spinal cord diseases results in positive outcomes.26,35,36,48,73,74 Better 
results have been obtained with cells differentiated towards a Schwann-like cell 
phenotype, based on histological and functional analyses.44,50,75 This emphasizes the 
importance of cell therapy as a promising alternative to nerve grafting. 
 
The processes by which undifferentiated MSCs or differentiated MSCs increase nerve 
regeneration have not entirely been determined. It is known that MSCs possess certain 
features that allow them to enhance tissue regeneration. When transplanted after 
sciatic, femoral or facial nerve transection models in rats, MSCs appear to promote the 
pattern for axonal regeneration and myelin production, as compared to controls 
(usually, the contralateral limb or facial nerve). Quantitative morphometric evaluation 
of the nerve involves axonal count and axonal diameter; the evaluation of myelin 
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thickness provides extra information.76 These parameters seem improved on 
laboratory animals that had been transplanted with MSCs after a nerve injury, when 
compared to untreated controls. Functional analyses testing strength, length of stride, 
and coordination are also superior results to the control limbs and to the animals that 
were not treated with cell therapy.50,75 
 
When the treatment consists of transplantation of purified Schwann cells from a fresh 
peripheral nerve, or transplantation of Schwann cell-differentiated MSCs, the 
aforementioned histological and functional results are superior to those obtained with 
undifferentiated MSCs in laboratory animals.44,48,50,75  
 
Delivery method. Cell therapy via transplantation of MSCs is one of the various 
auxiliaries within the field of regenerative medicine. Other alternatives for aiding in 
tissue repair include the use of other types of cells, platelet rich plasma (PRP), grafts, 
scaffolds, and nanoparticles. Tissue engineering, for example, uses a combination of 
transplanted cells, engineered scaffolds and biochemical factors to replace an injured 
tissue or organ. Consequently, there is increasing interest on the design of 
biomaterials capable of supporting cells and of promoting the delivery of factors 
(growth factors, neurospheres, etc.) that most appropriately improve nerve 
regeneration. 
 
In laboratory animals the use MSCs or Schwann cell-differentiated MSCs for treating 
peripheral nerve injuries (with or without a scaffold or autograft) is commonly 
performed in situ immediately after nerve injury. There are several reports, 
conversely, on clinical trials and experimental designs on peripheral nerve and spinal 
cord injuries in which the transplantation of cells occurred intrathecally, by 
administering the cells into the cerebrospinal fluid (CSF); intra-arterially (IA), or 
intravenously (IV), via systemic or local administration.74,77,78 When MSCs are 
transplanted IV, they are caught in the capillary beds of several tissues, mainly the 
lungs.79 It is important to note that these cells were undifferentiated MSCs. To the 
knowledge of the author, there are no reports regarding the administration of 
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Schwann cell-differentiated MSCs via IV, CSF or IA routes for treating either spinal 
cord or peripheral nerve injuries.  
 
There are no current reports regarding the most suitable method of delivery of MSCs 
for peripheral nerve disease in horses. Likewise, there are not reports regarding the 
use of Schwann cell-differentiated MSCs for nervous tissue repair in horses. 
 
Tracking MSCs after transplantation. The mechanisms by which MSCs are able to 
migrate, stay (“homing”) and repopulate a tissue are not completely understood. In 
vitro and in vivo studies have revealed that stromal derived factor-1 (SDF-1) and its 
interaction with receptors CXCR1, 4 and CCR2 and 5, play roles in stem cell motility 
and development. Furthermore, the expression of various types of adhesion 
molecules, such as integrins, ICAMs and VCAMs, are also involved in stem cell 
mobilization homing and proliferation.80-82 The phenomena of migration and homing 
were evident in the repair of heart, bone, cartilage, CNS and PNS.47,81 
 
For the sake of research it is important to be able to trace these cells after 
transplantation. Relying solely on functional analyses or by improvement of 
symptoms in humans does not assess the ability of cell therapy to contribute to tissue 
repair, especially if medications and physical therapy were part of the treatment. 
Methods to trace cells include labeling them with retroviral vectors to express 
fluorescent proteins, and the use of commercial dyes. These methods, however, 
require sacrificing of the animal to dissect the tissues. Alternatively, cells have been 
tracked in vivo by imaging them via magnetic resonance (MRI), computed 
tomography (CT), positron emission tomography (PET), and multiple photon 
microscopy.83,84  
 
Finally, the feasibility of these methods must be taken in consideration because of 
issues regarding affordability and availability of equipment and reagents, false 
positive signals, interference with the biological properties of MSCs, and most 
importantly, the ability to accomplish any of these scans in a horse. 
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Neurotrophic factors and nerve regeneration 
 
A particular interest has been given to the paracrine features of MSCs to secrete 
various trophic factors that aid in tissue repair. This is a topic of current focus because 
of the ability of MSCs (in this case, differentiated towards a Schwann cell phenotype) 
to be able to secrete neurotrophic factors that promote axonal regrowth and re-
myelination. These factors are thought to provide an appropriate microenvironment 
for neuronal nourishment, survival and proliferation.34,66,72  
 
Efforts have been made to understand the mechanisms of secretion, release and the 
properties that neurotrophic factors exert over neural cells, regardless of their sub-
type. The ultimate purpose is to remove damaged cells and to restore myelin and 
axonal regrowth after nerve injury by recruiting Schwann cells and other cells via cell 
signaling. The exact mechanisms for secretion and release are not completely 
understood yet. In vitro studies strengthen this hypothesis, after revealing that MSCs 
from human adipose tissue or bone marrow are capable of expressing neurotrophic 
factors and that they promote neurite process outgrowth when these cells are co-
cultured with injured nervous tissue.30,33,34,53 
 
Some of the growth factors that have recently been investigated because of their effects 
on nervous tissue repair are: NGF, brain-derived neurotrophic factor (BDNF), glial 
cell line-derived neurotrophic factor (GDNF), ciliar neurotrophic factor (CNTF), ILGF-
1, and VEGF. Briefly, NGF acts on neurons to stimulate their proliferation and 
differentiation; its action is potentiated when combined with scaffolds made of 
biomaterials.85 Similarly, BDNF enhances MSC differentiation towards cells of 
neuronal lineage in vitro, after nerve injury.85,86 In nerve fibers that were 
experimentally transected, it was found that GDNF promotes myelination and axonal 
re-growth on the early stages of the injury.87 Finally, CNTF, ILGF-1 and VEGF are 
auxiliaries of nerve regeneration and survival, the last one mainly due to its location 
between nerve fibers and blood vessels during nerve regeneration.31,88 
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Overall, the ability of MSCs to inhibit the immune response created after allogeneic 
transplantation, as well as their ability to contribute to tissue repair by direct or 
indirect mechanisms makes MSCs an attractive therapeutic alternative in the field of 
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CHAPTER II: 
DIFFERENTIATION OF EQUINE MESENCHYMAL STROMAL CELLS INTO 
NEURAL CELLS: POTENTIAL FOR CLINICAL APPLICATIONS 
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Studies have shown that mesenchymal stromal cells (MSCs) are able to differentiate 
into extra-mesodermal lineages, including neurons.  Positive outcomes were obtained 
after transplantation of neurally-induced MSCs in rats, rabbits and guinea pigs after 
nerve injury, but this is unknown in horses.  Our objective was to test the ability of 
equine MSCs to differentiate into cells of neural lineage in vitro, and to assess 
differences, if any, in morphology and lineage-specific protein expression.  
Additionally, we wanted to investigate if horse age and cell passage number affected 
the ability to achieve neural differentiation.  Bone marrow-derived MSCs were 
obtained from 3 young and 4 adult horses.  Following demonstration of stemness, 
MSCs were neurally-induced and microscopically assessed at 3, 6, 12, 24 and 48 h.  
Results showed that commercially available nitrogen-coated tissue culture plates 
supported proliferation and differentiation.  Morphological changes were observed as 
early as 3 hours and all the cells surviving the treatment displayed a neural crest-like 
cell phenotype.  Expression of neural progenitor proteins, nestin, vimentin, β3 tubulin 
and glial fibrillary acidic protein (GFAP), was assessed via western blot or 
immunofluorescence.  In our study, MSCs generated from young and middle-aged 
horses did not show differences in their ability to undergo differentiation.  The effect 
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of cell passage number, however, is inconsistent and further experiments are needed.  
Ongoing work is aimed to trans-differentiate these cells into Schwann cells for 
transplantation into a peripheral nerve injury model in horses.  The ultimate goal is to 
provide practical resources for treatment of neuropathies in horses. 
 





Spinal cord and peripheral nerve injuries in horses occur after trauma, 
toxic/metabolic and infectious diseases.  Less frequently, degenerative and hereditary 
diseases also pose a threat.  These events trigger an inflammatory cascade of events 
that results in poor performance, disability or death.  Additionally, the impact of 
peripheral nerve injuries in horses is reflected by big financial and emotional 
investments.  Peripheral nerves can be injured by thermal or chemical injuries, 
compression, crushing, stretching or transection.1,2  After injury, the blood-nerve 
barrier permeability increases and an inflammatory response is initiated resulting in 
proliferation of Schwann cells and activation of local macrophages that respond to 
tissue damage.2,3  Several of these cells secrete neurotrophic factors and other 
substances that eventually enhance axonal regrowth and re-myelination, depending 
on the magnitude of the lesion and the chronicity of it.1,2,4-10  A loss of axonal continuity 
along with external nerve structures (neurotmesis, in the Seddon classification) has 
the poorest prognosis for recovery.1  
  
Mesenchymal stromal cells (MSCs) from bone marrow and adipose tissue have been 
demonstrated to trans-differentiate into cells of other lineages other than mesodermal 
lineages.  In vitro research has shown the ability of rodent and human MSCs to acquire 
a neural crest-like cell phenotype after induction with specific culture medium.7-9,11-13  
Neural protein markers, mainly, vimentin, nestin, β3 tubulin and glial fibrillary acidic 
protein (GFAP) were expressed in these neurally-induced cells, although results from 
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different studies are contradictory and hence, inconclusive.10,13-18  Interestingly, a 
novel study involving the evaluation of K+ and Na+ currents in neural crest-like cells 
revealed that after chemical induction of rat MSCs, these cells appeared to have lost 
the aforementioned electrophysiological property when compared to non-induced 
MSCs; concluding that despite morphological and molecular changes similar to 
neural cells, these chemically induced cells lacked the functional properties of 
neurons.14  Nevertheless, several studies have shown positive correlation between in 
vitro and in vivo results.2,7,9,12,14,19-21  For instance, bone marrow and adipose-derived 
undifferentiated MSCs have revealed positive outcomes when these cells were 
allogeneically transplanted in neurologically injured rats, rabbits and dogs.2,9-11,18-
20,22,23  On the other hand, studies in rats have also shown beneficial responses and 
regain of nerve function after transplanting either chemically-induced MSCs into a 
Schwann cell-like phenotype, or pure Schwann cells obtained from fresh peripheral 
nerve tissue.9,11,23,24  It is important to mention, however, that in these studies cell 
therapy occurred immediately after nerve or spinal cord injury.   
 
To our knowledge, there are no reports in the literature that describe the ability of 
equine bone marrow-derived MSCs (eBM-MSCs) to differentiate into cells of neural 
lineage, or demonstrate the clinical benefits after transplantation into horses suffering 
from neuropathies.  We have previously reported that to improve the clinical 
outcomes related to stem cell therapies, it is important to assess the biology and 
function of MSCs prior to their application in clinical cases.25  In view of our long term 
goal of using equine MSCs in neuropathies, the present study was designed as a first 
step to evaluate the proliferation and survival of eBM-MSCs in vitro, and their ability 
to differentiate into neural crest-like cells after chemical induction.  We compared 
these properties and assessed changes, if any, in horses (donors) of two age groups.  
Additionally, we compared changes in neural differentiation relative to the passage 
number of eBM-MSC cultures.  We used the expression profiles of the neural 




Materials and methods 
 
1. Animals and bone marrow aspiration.  Bone marrow aspirates were obtained from 
the sternum of 2 young mixed breed (range: 1-4 years old) and 4 adult American 
Quarter Horse (range: 9-13 years old) mares, and 1 young American Quarter Horse 
gelding as described previously.26  All procedures were carried out as per an approved 
protocol by the Institutional Animal Care and Use Committee of the University of 
Tennessee, Knoxville, TN.  Briefly, horses were sedated with 0.01-0.02 mg/kg of 
detomidine hydrochloride, intravenously.  A 10 cm band was clipped and surgically 
prepared on the ventral aspect of the sternal area. Three mL of 2% lidocaine 
hydrochloride were injected subcutaneously and intramuscularly at the level of the 
5th or 6th sternebrae at the ventral midline, followed by a stab incision with a 15 blade 
on the skin, subcutaneous tissue and musculature.  A Jamshidi needle was inserted 
perpendicular to the skin until it reached the periosteum. The needle was then forced 
into the sternum and bone marrow from either the 5th or the 6th sternebrae was 
obtained by gentle aspiration with a syringe loaded with 1000 IU/10 mL of heparin 
sulfate. 
 
2. Isolation and expansion of MSCs.  These procedures were as described earlier.25-27  
Briefly, bone marrow aspirate was diluted with 1X PBS and layered on top of the 
lymphocyte separation media, Ficoll™.  After centrifugation at 200g for 20 min at 
room temperature, the buffy coat containing the mononuclear cells (MNCs) was 
obtained.  The MNCs were resuspended in growth media containing Dulbecco’s 
modified Eagle medium/Ham’s F-12 [(DMEM-F12), Cellgro™, Manassas, Virginia], 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  Roughly 20x106 cells 
were seeded in 175 cm2 vented tissue culture flasks (Thermo Scientific™, Rochester, 
NY), and maintained at 37 °C and 5% CO2. First growth medium change was carried 
out between 5-7 days when clusters of colonies were visible under the phase contrast 
microscope.  When 70-80% confluency was reached, the cells were harvested with 
0.25% trypsin-EDTA for 2 min at 37 °C (passage 1: P1).  After centrifugation, the cell 
pellet was reconstituted with either the growth medium to start a new experiment, or 
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with freezing media containing 50% DMEM-F12, 50% FBS and 5% DMSO for 
cryopreservation under liquid nitrogen for future experiments.  These steps were 
repeated as needed in order to obtain cells from passage 2 to 4 (P2 to P4; low passage), 
and cells from P9-P12 (high passage) and used in future experiments. 
 
3. Demonstration of stemness on low passage equine MSCs from 7 donors: 
a) Colony forming unit assay (CFU).  Passage 1 of equine MSCs were seeded at a 
density of 1x106 in 100mm tissue culture dishes (Thermo Scientific™, Rochester, NY) 
and maintained in growth medium for 7 to 10 days until clusters of colonies were 
observed.  The medium was replaced after every 2-3days.  Colonies were fixed with 
4% paraformaldehyde and stained with 0.5% of crystal violet (Sigma-Aldrich®, Saint 
Louis, MO).  After staining, the dishes were allowed to air dry and images were 
acquired with a Fujifilm™ LAS-4000 imaging system (GE Healthcare Life Sciences).  
 
b) MTS proliferation assay.  Low passage (P2-P4) of equine MSCs were seeded at a 
density of 2x104 per well in a 24-well tissue culture plate.  The medium was replaced 
every 2-3 days.  Cell proliferation was measured at 2, 4 and 7 days post seeding.  A 
CellTiter 96 Aqueous non-radioactive (MTS) assay (Promega™, Madison, WI) was 
used following the manufacturer instructions.  Briefly, MTS reagent in a 5:1 ratio 
relative to the media was added to each well and incubated for 3 h at 37 ° C and 5% 
CO2.  The absorbance at 490 nm was measured and data was obtained using Gen5 
data analysis software (Biotek®, Winooski, Vermont).  Growth medium only with no 
cells was used as a blank to correct the readings for each of the samples. 
 
c) Induction of adipogenic, osteogenic and chondrogenic differentiation.  Low 
passage (P2-P4) of equine MSCs were seeded at a cell density of 2x105cells in 60 mm 
tissue culture dishes (BD Falcon™, New Jersey) and maintained at 37 ° C and 5% CO2 
in growth medium. When the cells were roughly 70% confluent, the medium was 
removed and was replaced with lineage-specific differentiation media as described 
earlier.27  Briefly, adipogenic differentiation was induced by the addition of DMEM-
F12 medium containing 15% rabbit serum, 1 μmol/L dexamethasone, 10 μg/mL 
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recombinant human insulin, 20 μmol/L indomethacin, and 0.5 mmol/L 3-isobutyl-1-
metylxanthine.  Osteogenic differentiation was induced by the addition of DMEM-F12 
medium containing 100 nmol/L /mL of dexamethasone, 0.25 mmol/L ascorbic acid 
and 10 mmol/L β-glycerophosphate.  Chondrogenic differentiation was induced by 
the addition of DMEM-F12, 100 nmol/L of dexamethasone, 0.25 mmol/L ascorbic acid 
and 5 ng/mL transforming growth factor β1.  Medium was replenished every 2-3 days 
and differentiation was monitored via microscopic evaluation.  Undifferentiated 
MSCs maintained in regular growth medium without any differentiation reagents, for 
the same number of days served as controls.  Differentiation was confirmed using 
lineage-specific cell staining using previously published methods.27  Specifically, 
adipogenic cells were stained with Oil Red-O, osteogenic cells were stained with 
Alizarin red, and chondrogenic cells were stained with Alcian blue.  Images were 
acquired with an electronic camera (Nikon™ DS-Fi2, Japan) connected to a Zeiss® 
microscope and evaluated with the NIS-Elements™ imaging software (Nikon™). 
 
4. Neural differentiation on low and high passage equine MSCs from selected donors. 
These experiments were performed on equine MSCs obtained from one young and 
one middle-aged donor.  The donors were chosen based on their rates of proliferation 
as demonstrated by the MTS assay described above.  
 
a) Cell culture.  Low (P2) and high (P9) of equine MSCswere seeded at a cell density 
of 8 to 10x106 into either polystyrene, or Primaria™ nitrogen-coated 100 mm tissue 
culture dishes (Becton Dickinson Labware, Bedford, MA).  Cells were maintained in 
regular growth medium at 37 ° C and 5% CO2, for at least 48 h to allow attachment.  
Neural differentiation was induced using a combination of previously described 
methods 13,18.  Briefly, the growth medium was removed and cells were pre-incubated 
with medium containing DMEM-F12, 20% FBS and 1 mM β-mercaptoethanol (Sigma-
Aldrich®) at 37 °C and 5% CO2, for 18-24 h.  Subsequently, the cells were induced by 
the addition of the neural medium containing DMEM-F12, 2% DMSO and 200 µM 
butylated hydroxyanisole (BHA; Sigma-Aldrich®) and cells were incubated at 37 °C 
and 5% CO2, for 3, 6, 12, 24 or 48 h.  Undifferentiated MSCs maintained in regular 
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growth medium for the same number of hours were used as corresponding controls.  
Undifferentiated and differentiated cells were assayed at the end of each experiment 
as described below. 
 
b) Nuclear/cytoplasmic staining.  Nuclear/cytoplasmic fluorescent staining was used 
to show the neural-cell like morphology of MSCs after neural differentiation.  Low 
and high passages of equine MSCs were seeded at a density of 1.25x106 on Primaria™ 
nitrogen-coated 60 mm tissue culture dishes and maintained in regular growth 
medium at 37 °C and 5% CO2, for at least 48 h to allow attachment.  When cells were 
80-90% confluent they were chemically induced for neural differentiation as described 
above.  Undifferentiated control MSCs described above were maintained with regular 
growth medium.  For cytoplasmic staining, neurally-induced and undifferentiated 
MSCs at 12 h were stained with 5 µg of WGA (wheat germ agglutinin, Alexa Fluor® 
488 conjugate; Life Technologies™) for 10 min, at room temperature.  To stain the 
nucleus, cells were further washed and stained with 5 µg of TO-PRO®-3 iodide stain 
(Life Technologies™, Grand Island, NY) for 10 min, at room temperature.  After 
washing, the cells were mounted with Slowfade® Gold antifade reagent (Molecular 
Probes®, Grand Island, NY) and images were obtained with a laser scanning spectral 
confocal microscope (Leica TCS SP2; Leica Microsystems©, Wetzlar, Germany), at 20x 
and 63x magnification. 
 
c) Protein extraction and western blot.  Total cell lysates were prepared from 
undifferentiated and neuronally-induced equine MSCs from low and high passages 
12 h post-differentiation using standard protocols.  Cells on each dish were gently 
washed with HBSS buffer and collected via cell scraping.  To obtain total proteins in 
each sample, cells were lysed in 200 µL of RIPA buffer (Boston Bioproducts™, 
Ashland, MA), sonicated and supernatants were obtained by centrifugation.  Total 
protein in each sample was quantitated and concentrations were obtained using 
modified BCA assay at 660nm (Pierce®, Thermo Scientific™).  Equal concentrations 
of total proteins from neurally-induced and undifferentiated MSCs were 
electrophoretically separated in a 10% acrylamide gel and transferred onto 
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nitrocellulose membranes.  The membranes were blocked with 5% bovine serum 
albumin (BSA) and incubated with mouse anti-β3 tubulin (1:1000; Santa Cruz™) and 
mouse anti-GFAP (5 µg/10 mL; 1:1000; BD Pharmingen™).  HRP goat anti-mouse IgG 
(1:5000; BD Pharmingen™) was used as the secondary antibody.  Antigen detection 
was performed after exposure to ECL-2 reagent (Pierce®, Thermo Scientific™).  Beta 
actin was used as a loading control. 
 
d) Immunofluorescence (IF).  Low and high passages of equine MSCs were seeded at 
a density of 1.25x106 on Primaria™ nitrogen-coated 60 mm tissue culture dishes and 
maintained in growth medium at 37 °C and 5% CO2, for at least 48 h to allow 
attachment.  When cells were 80-90% confluent they were chemically induced for 
neural differentiation as described above.   Undifferentiated MSCs used as controls 
were maintained with regular growth medium.  Neurally-induced and 
undifferentiated MSCs were fixed with 4% paraformaldehyde, permeabilized with 
0.1% Triton X-100 (Sigma®) for 10 min, at room temperature, and blocked with 5% 
normal serum for 30 min, at room temperature.  Cells were washed and incubated 
overnight with 5 µg/sample of primary antibodies against nestin (BD Pharmingen™) 
and vimentin (BD Pharmingen™), at 4 °C.  After washing with HBSS buffer, cells were 
incubated with the secondary antibody (Alexa Fluor® 647 donkey anti-mouse IgG at 
5 µg per sample; BD Pharmingen™) for 20 min, at room temperature.  The cells were 
mounted with Slowfade® Gold antifade with DAPI reagent (Molecular Probes™) and 
images were obtained with a laser scanning spectral confocal microscope (Leica TCS 
SP2; Leica Microsystems©, Wetzlar, Germany) 
 
Statistical analysis.  A two-tailed Student’s t-test was used to compare the average of 
neural – like cells, which adhered to the polystyrene-coated with those to the 
Primaria™ nitrogen-coated tissue culture plates.  Similarly, the expressions of nestin 
and vimentin between cells of P2 and P9 from middle-aged horse, and between cells 
of P2 from young and middle-aged horse were compared from the IF data.  The 
expressions of the two proteins were also compared between undifferentiated and 
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a) Stemness of equine MSCs 
The stemness of cells from all equine MSC cultures was assessed solely in low passage 
cells.  Once the properties of stem cell were demonstrated, only 1 donor from each 
group (young and middle-aged) was selected and the population of MSCs was 
passaged for neural experiments.     
 
Morphology.  Equine MSC cultures expanded from the bone marrow harvest adhered 
to the polystyrene surface and displayed spindle-shaped fibroblastic morphology.  No 
morphological change was observed in eBM-MSC cultures generated from young and 
middle-aged donors.  
  
Proliferation.  Equine MSCs from young (Figure 2.1: horses 1-4) and middle-aged 
donors (Figure 2.1: horses 5-7) were capable of self-renewal as demonstrated by their 
proliferation and viability measured at days 2, 4, and 7.  As demonstrated in the figure, 
there was a 3-6 fold increase, in absorbance for all the donors over a period of 7 days 
confirming their proliferation and viability.  As expected and previously reported 
cellular proliferation, was variable between each horse. Horses that showed the 
highest proliferation and thus generating enough numbers of MSCs in a given period 




Figure 2.1.  MTS proliferation assay on eBM-MSCs 
 
 
CFU. Equine MSCs of P1 of young and middle-aged horses were capable of growing 
in clusters over the polystyrene - coated tissue culture dishes at day10, suggesting that 
the eBM-MSC cultures established represent the MSCs or the progenitor cells.  A 
representative CFU assay is shown (Figure 2.2). 
 
 




Mesodermal tri-lineage differentiation.  Low passage equine MSCs from both young 
and middle-aged donors were capable of differentiation into adipogenic, 
chondrogenic and osteogenic cells under lineage-specific chemical induction (Figure 
2.3).  At day 5, adipogenic cells displayed a typical pattern of lipid droplet formation, 
which could be stained with oil-red-o.  Osteogenic and chondrogenic differentiation 
potential was confirmed by Alizarin red and Alcian blue staining, respectively after 
10-15 days of chemical induction.  No morphological differences were observed 
between horses.  Variability existed, however, on the time of reaching a differentiated 
phenotype, as judged by specific staining.  Undifferentiated controls remained with a 
spindle fibroblastic shape at all times and were not positive for lineage-specific 
staining.  Of importance and in accordance to our previously published paper25, 
osteogenic and chondrogenic differentiation of MSCs from one middle-age donor 
(horse 6), consistently occurred earlier than the rest. 
 
All data presented above confirm that equine MSCs generated from each donor are 





Figure 2.3.  Mesodermal tri-lineage differentiation assays of eBM-MSCs 
 
 
b) Neural differentiation  
After ensuring selection of MSCs from low passage cells from the previous 
experiments, eBM-MSCs were further expanded, passaged, and tested for neural 
differentiation.   
 
Neural crest-like cell morphology.  For easy visualization, fluorescence microscopy 
was used to show an intact nucleus and a “healthy” cytoplasm. TO-PRO®-3 stain, the 
most sensitive probe for nucleic acid detection, along with WGA, specific to the cell 
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membrane, were used to demonstrate the nucleus and the cytoplasmic structure of 
the neural-like cells.  Low and high passage eBM-MSCs from the selected young and 
middle-aged horses were capable of adopting neural crest-like cell morphology as 
early as 3 h after chemical induction.  These morphological characteristics consisted 
of elongation of the cell, cell body contraction, and formation of one or multiple cell 
processes (Figure 2.4).  After 12 h of neural differentiation, all the cells displayed 
neural crest-like cell morphology.  Moreover, these cells appeared to grow in a cluster 
in a mesh-like pattern.  Undifferentiated controls had the spindle fibroblastic 
appearance of a MSC.   No differences were microscopically observed on the 
phenotypical characteristics of neural crest-like cells of low passage between young 
and middle-aged horses.  When analyzing high passage cells, subtle morphological 
differences were detected.  The majority of these cells also displayed the 
aforementioned neural crest-like cells characteristics; however, they seemed to lose 
their cytoplasmic integrity and some of them appeared rounded and small.  Nuclear 
and cytoplasmic staining helped in visual assessment of the morphological 
characteristics of these differentiated cells (Figure 2.5).  These morphological 
differences were more specific to the passage numbers, i.e. can be attributed to the 
process of cell culture itself, and not to the age of the donor.   
 
 




Figure 2.5.  Nuclear (TO-PRO-3-iodide)/cytoplasmic (WGA) staining of neural crest-
like eBM-MSCs (a, b, c) and undifferentiated eBM-MSCs (d, f). Scale bar= 25 μm 
 
 
Finally, as judged by the numbers of cells adhered to the 2 different types of tissue 
culture plates; the nitrogen-coated plates (Primaria™) significantly enhanced cell 
survival and proliferation roughly, 2-fold higher than the polystyrene – coated plates 







Figure 2.6. Nuclear (TO-PRO-3-iodide)/cytoplasmic (WGA) staining of neural crest-
like eBM-MSCs on Primaria™ (a) and polystyrene-coated (b) tissue culture plates. 
Scale bar= 100 μm 
 
 
Expression of neural progenitor proteins.  The expression of vimentin was confirmed 
by IF (Figures 2.7 and 2.8).  Vimentin was expressed by cells of low passage for both 
age groups with no significant differences (P=0.7653); cell passage number did not 
affect vimentin expression on the middle-age horse (P=0.7774), and no difference on 
vimentin expression was noted between undifferentiated MSCs and neurally-induced 




Figure 2.7.  Expression of vimentin in undifferentiated (top row) and differentiated 
low passage eBM-MSCs (bottom row). Scale bar= 25 μm 
 
 
Figure 2.8.  Expression of vimentin in undifferentiated (top) and differentiated 
(bottom) high passage eBM-MSCs. Scale bar= 25 μm 
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Immunoblot analysis was carried out to assess the expression of GFAP and β3 tubulin 
(Figure 2.9).  Differentiated cells from low passaged cells obtained from middle aged 
and young MSC cultures showed the expression of both the GFAP and β3 tubulin.  β3 
tubulin, was not expressed in the differentiated cells from high passaged cells 
obtained from the young MSC culture.  The importance, if any, is not known at this 
time.  Interestingly, low and high passaged undifferentiated cells generated from both 




Figure 2.9.  Western blot analysis of the expression of neural progenitor proteins β3 
tubulin and GFAP in differentiated (a) and undifferentiated (b) eBM- MSCs generated 
from low and high passaged cells from middle-aged (lanes 1 and 2, respectively) and 
young (lanes 3 and 4, respectively) horses 
 
 
We were not able to detect nestin expression by western blot analysis, even when 3 
different primary antibodies with various dilutions (1:1000, 1:2000) or secondary 
antibody concentrations (1:5000, 1:10 000).  Interestingly, nestin expression was 
evident in undifferentiated and neurally-differentiated MSCs of low and high 
passages for both age groups by IF (Figure 2.10).  Nestin expression on cells of low 
passage for both age groups was observed with no significant differences (P=0.7325).  
Additionally, cell passage number did not affect significantly the expression of nestin 
on the middle-aged horse (P=0.3467), and no difference on nestin expression was 
noted between undifferentiated MSCs and neurally-induced MSCs for young 
(P=0.9616) or middle-aged (P=0.0830) horses.  A perinuclear location of nestin was 
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evident on undifferentiated and neurally-differentiated MSCs of low passage, and on 
undifferentiated MSCs of high passage both age groups (Figure 2.10).  The location of 
nestin in neurally-differentiated cells of high passage, however, was inconsistent, with 
some cells displaying a perinuclear location and others showing a more diffuse, 
cytoplasmic expression (Figure 2.11).  It is possible that cells of high passages undergo 
changes that alter the structure of some filamentous proteins (i.e. nestin).  
 
 
Figure 2.10.  Expression of nestin in differentiated (top) and undifferentiated (bottom) 






Figure 2.11.  Expression of nestin in differentiated (top) and undifferentiated (bottom) 





Peripheral nerve injuries are a cause of poor performance in horses. These injuries are 
difficult to manage and treatment mostly relies on physical therapy and anti-
inflammatories; however, the long-term effects are time and personnel consuming.  
The development of neuronal cells is divided into various stages.  After determination 
of their fate, these cells migrate to specific locations of the nervous system and 
accomplish different functions.18,28  Previous studies have demonstrated that 
undifferentiated MSCs are able to express some neural protein markers, leading to the 
question whether MSCs are in advance committed to a neural lineage.29-32  Moreover, 
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as neural progenitors develop into more specialized cells, changes in protein markers 
are also evident.4,13,17,30,33  
 
Adipose-derived and bone marrow-derived MSCs from humans and rats are able to 
differentiate into neural lineages.4,13,18,28,29,33-37  Several reports have described 
different methods of chemical induction for neural differentiation.13,30,33,37,38  Medium 
containing trans-retinoic acid or butylated hydroxyanisole is the most frequently 
reported.  Additionally, co-culture systems with MSCs and cells from nervous tissue 
have also proven successful for the induction of neural differentiation of MSCs.29  
 
We conducted chemical induction of bone marrow-derived MSCs from young and 
middle-aged horses to characterize their viability and plasticity into mesodermal and 
neuronal (ectodermal) lineages.  Cells from all horses were capable of self-renewal 
and underwent differentiation into adipogenic, osteogenic and chondrogenic 
lineages.  This was consistent with a previous report published from our laboratory25 
and, thus, confirmed the stemness of the cultured MSCs.  For the neural 
differentiation, fluorescence microscopy revealed that morphological changes were 
observed as early as 3 h after chemical induction in all horses.  Using 
nuclear/cytoplasmic staining we were able to demonstrate that differentiated cells 
acquired a neural crest-like cell morphology in which retraction of the cell soma and 
formation of multiple cell processes were observed.  Most importantly, the 
proliferation of differentiated MSCs under the neural media was higher on the 
nitrogen-coated plates (Primaria™) than on the polystyrene tissue culture plates, 
suggesting stabilization of the cell membrane by providing a positive charge.  
 
By the combination of western blot and IF analyses, we found that all MSCs, 
undifferentiated and differentiated, expressed neural progenitor markers, namely, 
vimentin, nestin, GFAP and β3 tubulin were evident.  The expressions of GFAP and β3 
tubulin in undifferentiated MSCs were particularly interesting and data is supported 
by previous studies in rats and humans, suggesting their ability for neuronal 
differentiation.39,40  Nestin has been shown to be expressed in muscle and neural 
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progenitor cells, as well as in highly proliferative cells (i.e. following injuries, high 
mitotic rate, etc.) or undergoing development.41-43  In IF data, nestin subjectively 
appeared weaker in cells from high passage than cells from low passage, suggesting 
the loss of cellular mechanisms for proliferation and plasticity as the cell ages.  We 
detected a perinuclear location of nestin in undifferentiated and neurally-
differentiated MSCs from P2.  In differentiated cells from P9 in nestin location 
extended from the perinuclear region towards other regions in the cytoplasm.  This 
was similar to previous reports43,44 and may suggest post-translational modifications 
of nestin42-44, the analysis of which was beyond the scope of our study.  Similarly, the 
effect of cell passage number on the expression of these markers also suggested 
modifications or structural changes as the cells age, but further studies are needed to 
confirm this. 
 
Our study mainly relies on morphological changes and neural marker protein 
expression to describe the events occurring during neural differentiation of eBM-
MSCs.  Our results agree with previous in vitro studies performed in bone marrow-
derived MSCs from rat, human and dogs in which eBM-MSCs are chemically induced 
into cells that display morphologic, genetic and protein characteristics of neural 
progenitors.  To our knowledge, this is the first report describing the plasticity, 
morphological characteristics and protein expression changes of eBM-MSCs into cells 
of neural lineage after chemical induction.  We have not only demonstrated the in 
vitro differentiation patterns but also validated the cross-reactivity of human neural-
specific antibodies with equine protein samples.  Further studies are however, 
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Peripheral nerve injuries cause poor performance in horses and their outcome is 
frequently unfavorable. Autografting a peripheral nerve is the ideal approach for 
repairing a nerve. This, however, represents difficulties in obtaining enough tissue 
and in causing morbidity to the donor site. Alternative approaches include the 
insertion of biocompatible scaffolds and transplantation of mesenchymal stromal cells 
(MSCs) into the affected individual. Transplantation of MSCs differentiated into 
Schwann-like cells is still under investigation, with promising results in laboratory 
animals. There are no current reports of bone marrow-derived MSCs from horse and 
their ability to differentiate into Schwann-like cells. Likewise, there are no reports 
describing a model for peripheral nerve injury in horses. Our objectives were to 
evaluate the ability of equine bone marrow-derived MSCs to differentiate into 
Schwann-like cells, to propose a model for peripheral nerve injury in horses, and to 
evaluate the effects of MSCs on nerve regeneration after transplantation in situ. Equine 
bone marrow-derived MSCs were differentiated into Schwann-like cells for 7 days, 
and assessed via microscopy, immunofluorescence and western blot by using 
Schwann cell markers. Results showed that MSCs from young and middle-aged 
horses displayed Schwann cell morphology and were able to express glial fibrillary 
acidic protein and S-100b at day 7. Furthermore, histological analyses were performed 
on peripheral nerve sections from 3 horses, 45 days after nerve transection followed 
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by in situ transplantation of undifferentiated MSCs. Our fundamental goal is to 





In veterinary medicine, horses can suffer peripheral nerve injuries after traumatism, 
metabolic, toxic, hereditary, degenerative and infectious diseases. The sequels of 
nerve injury in horses are frequently undesirable, resulting in poor performance, 
disability or even death. This, consequently, causes a profound financial and 
emotional impact afterwards.  
 
Peripheral nerves have the ability to regenerate after injury due to the secretion of 
cytokines and neurotrophic factors from the damaged cells (mainly by Schwann cells), 
and because phagocytosis is initiated by local macrophages to remove cell debris.1-3 
The regaining of nerve function, however, will depend on the magnitude of the nerve 
lesion and its chronicity.4 The prognosis for recovery is poorest when a nerve is 
transected and its nerve fibers and surrounding fascia (connective tissue) have been 
completely disrupted. This is known as neurotmesis in Seddon’s classification for 
peripheral nerve injuries.5,6 Surgical techniques for nerve repair involve suturing the 
nerve stumps together or inserting a graft that bridges the gap. In tissue engineering, 
some of the most commonly utilized materials for fabricating grafts or scaffolds 
consist of vein, artery, nerve, silicone, collagen, laminin, gels made of platelet rich 
plasma (PRP), and synthetic polymers.7,8 Regardless of the technique used or the 
duration of the nerve repair, clinical results are often disappointing.6,9  
 
Currently, research regarding cell therapy with mesenchymal stromal cells (MSCs) 
suggests this might be an alternative approach for nervous tissue repair, including 
spinal cord and peripheral nerve injuries.10-12 The neuroprotective effects of MSCs 
have been widely described, and they involve anti-inflammatory, 
immunomodulatory, angiogenic and nurturing mechanisms.13-16 Furthermore, MSCs 
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from bone marrow and adipose tissue are able to differentiate into Schwann-like cells 
after chemical induction with specific conditions.12,17,18 In experimental models in 
laboratory animals, when Schwann-like cells are transplanted into nervous lesions, 
the results for axonal and myelin repair as well as the sensory and motor functions, 
appear promising. This is believed to be consequence of the secretion of specific 
neurotrophic factors that promote nerve repair.11,12,16 
 
To our knowledge, there are no reports in the literature regarding outcomes of 
peripheral nerve injuries after cell therapy in the horse.  Similarly, we can find no 
reports that describe the ability of equine bone marrow-derived MSCs (eBM-MSCs) 
to differentiate into myelinated Schwann-like cells. We have recently reported that 
eBM-MSCs are able to display morphological and protein characteristics of neural 
progenitors.  In this preliminary study, we evaluated the ability of eBM-MSCs to 
differentiate into Schwann-like cells after chemical induction. Additionally, we 
propose a new model for peripheral nerve injury in the horse and its outcome after 
transplantation of undifferentiated MSCs. 
 
 
Materials and methods 
 
1. Animals.  Three healthy American Quarter Horse crossbred mares from our 
Institution’s teaching herd were used for the study.  The mares were transplanted 
allogeneic undifferentiated MSCs from a donor whose cells have been previously 
characterized.  These cells were transplanted immediately after the first surgery (see 
No. 2). All procedures were carried out as per an approved protocol by the 
Institutional Animal Care and Use Committee of the University of Tennessee, 
Knoxville, TN.   
 
2. Transection of the ramus communicans with the horses standing.  Horses were 
sedated with 0.01-0.02 mg/kg of detomidine hydrochloride and 0.01-0.02 mg/kg of 
butorphanol tartate, IV.  The palmar aspect of both metacarpal regions was prepared 
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for aseptic surgery and 2 mL of 2% mepivacaine hydrochloride were subcutaneously 
deposited adjacent to the medial palmar nerve and adjacent to lateral palmar nerve 
proximal to the palpable ramus communicans, palmar to the superficial digital flexor 
tendon (Figure 3.1).  A scalpel blade was used to create a cutaneous, longitudinal 
incision over the ramus communicans.  Using a 6 mm punch biopsy the center of this 
anastomotic nerve, which connects the medial and lateral palmar nerves, was 
removed and placed in formalin.  Following nerve transection, 10x106 allogeneic 
MSCs suspended in a volume of 1 mL of sterile saline were instilled into the fascia 
surrounding this nerve (Figure 3.2).  The contralateral transected nerve received an 
injection with the same volume of sterile saline (control).  The cutaneous incision was 
closed with staples, and the distal portion of the limbs was bandaged.  The horses 
received phenylbutazone (4.4 mg/kg, PO) at the time of surgery and the day after 
surgery (2.2 mg/kg, PO).  The bandage was changed every third day until the staples 
were removed at day 14. The horses underwent general anesthesia for complete 
removal of both ramus communicans approximately 45 days after the cell transplant.  
Briefly, the horses were induced with 0.5 mg/kg of xylazine and 2.2 mg/ kg of 
ketamine, IV. They were intubated, placed in lateral recumbence, connected to the 
ventilator and maintained with isofluorane.  A scalpel blade was used to create a 
cutaneous, longitudinal incision over the medial and lateral aspects of the ramus 
communicans of both fore limbs. The subcutaneous tissue and surrounding fascia were 
bluntly dissected and once the nerve was identified, it was exposed and transected 
with scissors. The nerves were placed in Carson’s fixative and sent to pathology for 
histological analyses. The horses received phenylbutazone (4.4 mg/kg, PO) prior to 
surgery and the day after surgery.  The bandages were changed every third day until 




Figure 3.1. Local anesthesia (nerve block) of the medial (a) and lateral (b) palmar 
nerves of a horse 
 
 
Figure 3.2. Dissection (a) and transection (b) of the ramus communicans of the fore limb 




3. MSCs.  Low passage (P1 to P4) bone marrow-derived MSCs previously 
cryopreserved from an allogeneic horse donor were used for cell expansion or for cell 
transplantation into the mares. These MSCs had been previously characterized, as 
described in the section of materials and methods of Chapter II (see “Demonstration 
of stemness on low passage equine MSCs from 7 donors”). 
 
4. Schwann cell differentiation. 
a) Cell culture.  Low passage (passage 1-5) equine MSCs were seeded at a cell density 
of 8 to 10x106 into 100 mm Primaria™ nitrogen-coated tissue culture dishes (Becton 
Dickinson Labware, Bedford, MA).  Cells were maintained in regular growth medium 
containing containing Dulbecco’s modified Eagle medium/Ham’s F-12 [(DMEM-
F12), Cellgro™, Manassas, Virginia], 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin, at 37 ° C and 5% CO2, for 48 h to allow attachment.  Neural 
differentiation was induced using a previously described method.12  Briefly, the 
growth medium was removed and cells were pre-incubated with medium containing 
DMEM-F12, 20% FBS and 1 mM β-mercaptoethanol (Sigma-Aldrich®) at 37 °C and 
5% CO2, for 18-24 h.  Subsequently, the cells were induced by the addition of the neural 
medium containing DMEM-F12, 10% FBS and 35 ng/mL all-trans-retinoic acid for 3 
days.  The medium was then replaced with DMEM-F12, 10%FBS and a cytokine 
cocktail containing: 5 μM forskolin, 200 ng/mL recombinant human heregulin-β1 
(HRG-β1), 5 ng/mL platelet-derived growth factor, and 10 ng/mL recombinant 
human basic fibroblast growth factor (all reagents from Sigma-Aldrich®), for 7 days, 
replacing the medium every 72 h. 
 
b) Nuclear/cytoplasmic staining.  Equine MSCs were seeded at a density of 8-10x106 
on 100 mm Primaria™ nitrogen-coated tissue culture dishes and maintained in 
regular growth medium at 37 °C and 5% CO2, for 48 h to allow attachment.  After 48h 
when cells were 80-90% confluent they were chemically induced for Schwann cell 
differentiation as described above.  Undifferentiated MSCs (control) mentioned above 
were maintained with regular growth medium.  For cytoplasmic staining, Schwann-
like cells and undifferentiated MSCs at 12 h were stained with 5 µg of WGA (wheat 
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germ agglutinin, Alexa Fluor® 488 conjugate; Life Technologies™) for 10 min, at room 
temperature.  To stain the nucleus, cells were further washed and stained with 5 µg of 
TO-PRO®-3 iodide stain (Life Technologies™, Grand Island, NY) for 10 min, at room 
temperature.  After washing, the cells were mounted with Slowfade® Gold antifade 
reagent (Molecular Probes®, Grand Island, NY) and images were obtained with a 
laser scanning spectral confocal microscope (Leica TCS SP2; Leica Microsystems©, 
Wetzlar, Germany), at 20x and 63x magnification.  
 
c) Protein extraction and western blot.  Total cell lysates were prepared from 
Schwann-like cells and undifferentiated MSCs at 12 h using standard protocols.  Cells 
on each dish were gently washed with HBSS buffer and collected via cell scraping.  To 
obtain total proteins in each sample, cells were lysed in 200 μL of RIPA buffer (Boston 
Bioproducts™, Ashland, MA), sonicated and supernatants containing total proteins 
were obtained by centrifugation.  Total proteins in each sample were quantitated and 
concentrations were obtained using BCA assay at 660nm (Pierce®, Thermo 
Scientific™).  Equal concentrations (20 μg per lane) of total proteins from Schwann 
cell-induced and undifferentiated MSCs were electrophoretically separated in a 12% 
acrylamide gel and transferred onto nitrocellulose membranes.  The membranes were 
blocked with 5% bovine serum albumin (BSA) and incubated with mouse anti-S-100b 
(1:1000; BD Pharmingen™), mouse anti-β3 tubulin (1:1000; Santa Cruz™) and mouse 
anti-GFAP (1:1000; BD Pharmingen™).  HRP goat anti-mouse IgG (1:5000; BD 
Pharmingen™) was used as the secondary antibody.  Antigen detection was 
performed after exposure to ECL-2 reagent (Pierce®, Thermo Scientific™).  Beta actin 
was used as a loading control. 
 
d) Immunofluorescence (IF).  Low passage (P1-P5) MSCs from young and middle-
aged horse were seeded at a density of 8 to 10x106 cells on 100 mm Primaria™ 
nitrogen-coated tissue culture dishes and maintained in growth medium at 37 °C and 
5% CO2, for at least 48 h to allow attachment.  When cells were 80-90% confluent they 
were chemically induced for neural differentiation as described above.   
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Undifferentiated MSCs used as controls were maintained with regular growth 
medium.  Schwann cell-induced and undifferentiated MSCs were fixed with 4% 
paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma®) for 10 min, at 
room temperature, and blocked with 5% normal serum for 30 min, at room 
temperature.  Cells were washed and incubated overnight with 5 µg/dish of primary 
antibodies against S-100b (BD Pharmingen™) and GFAP (BD Pharmingen™), at 4 °C.  
After washing with HBSS buffer, cells were incubated with the secondary antibody 
(Alexa Fluor® 647 donkey anti-mouse IgG at 5 µg per dish; BD Pharmingen™) for 20 
min, at room temperature.  The cells were mounted with Slowfade® Gold antifade 
with DAPI reagent (Molecular Probes™) and images were obtained with a laser 




5. Histological analysis of nerve tissue.  The central portion the ramus communicans 
transected from both fore limbs of each horse (n=3) during the first surgery was placed 
on Carson’s fixative for histological analyses. Approximately 45 days after cell 
transplantation, the whole nerve was collected from both fore limbs on these horses 





1. Schwann cell differentiation  
Schwann-like cell morphology.  For better visualization, fluorescence microscopy 
was used to show the integrity of nucleus and cytoplasm on the cells. TO-PRO®-3 
stain, the most sensitive probe for nucleic acid detection, along with WGA, specific to 
the cell membrane, were used to demonstrate the nucleus and the cytoplasmic 
structure of the Schwann-like cells.  Low passage MSCs from young and middle-aged 
horses were capable of adopting a Schwann-like morphology 7 days after chemical 
induction. The cells elongated until they displayed spindle-shape morphology and 
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one or 2 cell processes appeared (Figures 3.3 and 3.4).  At 4 days of chemical induction, 
some of these cells began displaying this morphology, but at 7 days, most of the cells 
were as described.  Moreover, these cells seemed to grow in a “whorl-like” pattern.  
Undifferentiated controls had the typical fibroblastic appearance of a MSC.   No 
differences were microscopically observed in the phenotypic characteristics of 
Schwann-like cells between young and middle-aged horses. Subjectively, 




Figure 3.3. Phase-contrast microscopy of Schwann-like cells (black arrows) from 







Figure 3.4. Nuclear (TO-PRO-3-iodide)/cytoplasmic (WGA) staining of equine 
Schwann-like cells. . Scale bar= 100 μm 
 
 
Expression of Schwann cell markers.  The expression of S-100b and GFAP was 
confirmed by IF in Schwann-like cells from young and middle-aged horses (Figure 
3.5). Immunoblot analysis via western blot also demonstrated the expression of S-
100b, GFAP and β3 tubulin on these Schwann-like cells. As reported in our previous 
work (see Chapter II), undifferentiated cells generated from young and middle-aged 
horses also expressed GFAP, suggesting that the ability of MSCs to differentiate into 
other cell lineages goes beyond of mesodermal lineages. The expression of S-100b was 






Figure 3.5. Expression of Schwann cell markers S-100b (red) and GFAP (green) in 




Figure 3.6. Western blot analysis of the expression of β3 tubulin, GFAP and S-100b on 
Schwann-like cells from middle-aged (lane 1) and young (lane 2) horses, and 
undifferentiated MSCs from middle-aged (lane 3) and young (lane 4) horses 
 
 
2. Peripheral nerve regeneration. 
Five micrometer thick sections of Carson’s fixed, paraffin embedded tissues from the 
sites of nerve transection and treatment, as well as adjacent segments of nerves, were 
examined by light microscopy. The adjacent nerves in all specimens were considered 
to be within normal limits (Figure 3.7). Both the saline and MSC treated sections in all 
specimens had seroma formation characterized by cleft like spaces rimmed by or 
partially filled by aggregates of fibrin overlain by/bordered by/ or partially infiltrated 
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by fibroblastic cells and macrophages (Figure 3.8). Both the saline and cell treated 
sections in all specimens had post traumatic, transactional neuroma formation 
characterized by haphazard streams, whorls and fascicles of small vessels, fibroblasts 
and Schwann cells (Figure 3.9). No localized or discrete population of undifferentiated 




Figure 3.7. Nerves adjacent to the transection sites: saline injected (left) and MSC 




Figure 3.8. Seromas at transection sites: saline injected (left) and MSC injected (right). 





Figure 3.9. Neuromas at transection sites: saline injected (left) and MSC injected 






Peripheral nerves can be injured by chemical, thermal or mechanical trauma.19 Direct 
traumatism, metabolic disease, or idiopathic disease such as damage to the branch of 
the left recurrent laryngeal nerve (laryngeal hemiplegia) appears to be the nerve 
injuries most commonly reported in the horse. Treatment with anti-inflammatories 
and physical rehabilitation are often unrewarding. In human medicine when the 
nerve fibers are transected, the ideal method for repair is closing the gap by suturing 
the nerve endings and their surrounding fascia, or by inserting an autograft.7 The use 
of autografts, however, is non-practical and can cause sequelae.20 
 
The field of regenerative medicine is developing possible alternatives for nerve repair 
by the use of cell transplantation alone or in combination with bioengineered 
materials with the purpose of providing proper environmental conditions for survival 
and proliferation of cells that will aid on nerve repair, particularly Schwann cells.16,21 
Based on experimental studies in laboratory animals, the transplantation of MSCs 
after peripheral nerve injury results in regain of motor and sensory nerve 
functions.11,16,22,23 Additionally, previous studies have demonstrated that MSCs are 
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capable of extra-mesodermal differentiation, including cells from neural lineage. 
Transplantation of MSCs differentiated into Schwann-like cells has revealed better 
results on nerve function and morphology after nerve injury.10,11,24   
 
We conducted chemical induction of low passage bone marrow-derived MSCs from 
young and middle-aged horses to describe their plasticity into Schwann-like cells. 
Phase-contrast and fluorescence microscopies revealed that morphological changes 
were evident seven days after chemical induction in all horses. Differentiated cells 
were elongated, with an oval-shaped cytoplasm, and the formation of one or multiple 
cell processes. These cells appeared to grow in patches as compared to the flat even 
layer that undifferentiated MSCs produce. 
 
Western blot and IF analyses revealed the expression of the Schwann cell markers S-
100b and GFAP in Schwann-like cells. Undifferentiated MSCs also expressed GFAP, 
as previously reported by our group (see Chapter II, manuscript under review), but 
not S-100b. This suggests that bone marrow-derived MSCs are able to differentiate 
into extra-mesodermal lineages25, including those from horses.  
 
Moreover, we created a core lesion at the center of the ramus communicans in both fore 
limbs of three horses. After this procedure, cell transplantation with allogeneic MSCs 
was immediately performed in one of the limbs on all horses. Approximately 45 days 
after these procedures, the horses underwent a second surgical procedure to re-
harvest the whole nerve on both fore limbs.  
 
The in vitro portion of this study mainly relies on morphological and Schwann cell 
protein markers to describe the events occurring during differentiation of equine bone 
marrow-derived MSCs into Schwann-like cells. Our results agree with experiments 
performed in bone marrow-derived MSCs from rats and humans, in which cells are 
able to undergo differentiation and express typical Schwann cell markers.3,17,24,26 
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The in vivo portion of this study proposes a model for acute peripheral nerve injury in 
the horse, which has not previously been reported. Additionally, we evaluated the 
effects on speed and pattern of nerve regeneration after transplantation with 
allogeneic MSCs. Cell transplantation with MSCs differentiated into Schwann-like 
cells was not possible due to poor viability of the cells (25%) after detachment from 
the tissue culture flasks. A method for optimizing collection of equine Schwann-like 
cells is necessary. Furthermore, no histological differences were observed between 
nerves treated with MSCs and saline (controls) after transection in all horses. 
Additionally, there was no evidence of undifferentiated MSCs in the nerves that were 
treated with MSC. 
 
There are several limitations when working with large animal models. In the present 
model for acute peripheral nerve injury in the horse, results are inconclusive due to 
the low number of horses used and due to other factors that could have been involved 
in nerve regeneration without the formation of seromas, such as surgical technique, 
anatomical region of the artificially injured nerve (the distal limb of the horse has less 
vasculature than other areas in the body), method of cell delivery, labeling and 
tracking of cells, etc. In retrospective, we consider that transecting the center of the 
ramus communicans with the horse under general anesthesia may provide a better 
exposure of this nerve and the opportunity to close the surrounding nerve sheath and 
inject the cells directly into the nerve. Likewise, closing the subcutaneous tissue may 
prevent the formation of seromas. 
 
To the knowledge of the authors, this is the first report describing the morphological 
features and protein expression changes of equine bone marrow-derived MSCs into 
Schwann-like cells. We have also validated the cross-reactivity of rat Schwann cell-
specific antibodies with protein samples from horse. Further studies are warranted for 
exploring the viability, homing, and functionality of both MSCs and Schwann-like 
cells after transplantation in horses with peripheral nerve injuries. Similarly, a 
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This research focuses on evaluating and optimizing the in vitro conditions necessary 
for equine bone marrow-derived MSCs to differentiate into cells of neural lineage. It 
also describes the use of neural markers on equine MSCs or on protein samples 
derived from equine MSCs, which has not been previously reported in the literature. 
Subsequent work focuses on further optimization of in vitro conditions necessary for 
committing these neural cells into Schwann cells. Finally, an in vivo project evaluating 
a model of peripheral nerve transection in horses is presented for the evaluation of 
nerve regeneration after undifferentiated MSCs are transplanted into the lesion 
immediately after nerve injury. 
 
Further research is required to investigate several aspects of peripheral nerve repair 
in horses, including the optimization of a method for obtaining viable equine 
Schwann-like cells after cultured in vitro, labeling of cells to track their migration after 
transplantation in horses, studying the effects of inserting a scaffold with MSCs after 
peripheral nerve injury in horses, and developing a practical and affordable method 
of delivery of MSCs in the horse. These studies should combine in vitro and in vivo 
findings for application in real cases in veterinary practice. The ultimate goal is to 
provide alternative methods for peripheral nerve regeneration by using cell therapy 
with MSCs and engineered biomaterials; consequently, improving not only the 
performance but also the quality of life of horses affected with peripheral nerve and, 
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